G0433

Infectious Agent Antigen Detection By Enzyme Linked Immunosorbent Assay ELISA Technique Antibody HIV 1 And Or HIV 2 Screening

HCPCS code G0433 represents a critical preventive laboratory procedure used for the screening of Human Immunodeficiency Virus Type 1 (HIV-1) and or Type 2 (HIV-2). This specific code describes the use of the Enzyme-Linked Immunosorbent Assay (ELISA), a highly sensitive laboratory technique designed to detect both HIV antibodies and potentially the p24 antigen in a patient's serum or plasma. HIV is a retrovirus that attacks the body's immune system, specifically the CD4 T cells, leading to Acquired Immunodeficiency Syndrome (AIDS) if left untreated. Early detection through screening is paramount for initiating life-saving antiretroviral therapy (ART) and preventing viral transmission. The ELISA method involves drawing a blood sample from the patient via venipuncture. The whole blood is processed in a laboratory to isolate the serum or plasma. This sample is then added to a microtiter plate pre-coated with specific HIV antigens or antibodies. If the patient's sample contains HIV antibodies or the p24 antigen, they will bind to the molecules on the plate. Following a series of incubation and washing steps to remove unbound materials, an enzyme-linked secondary antibody is introduced. A specific substrate is then added, which the enzyme converts into a detectable signal, usually a measurable color change. A spectrophotometer reads the intensity of this color, determining whether the sample is reactive or non-reactive. Code G0433 is strictly designated for screening purposes in asymptomatic individuals, including pregnant women and individuals at increased risk for HIV infection. It is not intended for diagnostic testing of individuals exhibiting symptoms of HIV or those with a previously established HIV diagnosis. Because ELISA tests can occasionally yield false positives due to cross-reactivity, any initial reactive result requires supplementary confirmatory testing, such as an HIV-1 and HIV-2 antibody differentiation immunoassay or a nucleic acid test, to finalize the diagnosis. Adhering to clinical guidelines ensures accurate prevention and patient management protocols.

Clinical Indications

  • Routine preventative screening for adults and adolescents aged 15 to 65 years.
  • Screening for pregnant women during the first prenatal visit and in the third trimester for those at increased risk.
  • Individuals seeking evaluation for sexually transmitted infections.
  • Individuals with high-risk sexual behaviors or multiple sexual partners.
  • Persons who inject drugs or share drug injection equipment.
  • Healthcare workers or individuals following a potential occupational exposure to bloodborne pathogens.
  • Patients being evaluated for pre-exposure prophylaxis initiation or continuation.

Procedure Steps

  1. Verify patient identity and confirm informed consent for HIV screening.
  2. Perform venipuncture to collect a sufficient volume of whole blood into an appropriate collection tube.
  3. Label the specimen accurately with patient identifiers and transport it to the laboratory.
  4. Centrifuge the blood sample to separate the serum or plasma from the cellular components.
  5. Dispense the prepared serum or plasma sample into the wells of the ELISA microtiter plate coated with HIV-specific antigens and antibodies.
  6. Incubate the plate at the required temperature to allow antigen-antibody binding.
  7. Wash the plate multiple times using an automated washer to remove unreacted serum proteins.
  8. Add the enzyme-conjugated anti-human antibody to the wells and incubate again.
  9. Wash the plate to remove unbound enzyme conjugate.
  10. Introduce the colorimetric substrate solution and allow the reaction to develop.
  11. Add a stop solution to halt the enzymatic reaction.
  12. Read the optical density of the wells using a spectrophotometer to determine reactive or non-reactive results.
  13. Report findings to the ordering physician and initiate confirmatory testing protocols if the result is reactive.

Coding Guidelines

  • Use G0433 specifically for HIV screening using the ELISA technique. Do not use for diagnostic testing of symptomatic patients; use appropriate CPT diagnostic codes for those encounters.
  • For Medicare beneficiaries, this code is covered as a preventive service without co-payment or deductible when appropriate screening diagnosis codes are used.
  • Do not report G0433 in conjunction with rapid HIV tests such as G0432 or G0435 for the same encounter unless clinically justified and supported by documentation.
  • Frequency of screening allowed by Medicare is typically once annually for individuals between 15 and 65 years old, or more frequently up to three times for pregnant women or individuals at high risk.
  • Ensure a screening diagnosis code is listed as the primary diagnosis on the claim.
  • If the screening test is reactive, subsequent confirmatory tests must be billed with appropriate diagnostic codes rather than screening codes.

Associated ICD-10 Codes